Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company advancing precision therapies for genetically defined cancers. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's innovative pipeline, including its lead menin inhibitor ziftomenib for acute myeloid leukemia (AML).
Access authoritative updates on clinical trial progress, regulatory milestones, and strategic collaborations. Our curated collection features official press releases, financial disclosures, and scientific presentations - all organized for efficient tracking of Kura's developments in targeted cancer treatment.
Key content categories include clinical trial results, FDA communications, research partnerships, and quarterly financial reports. The repository serves as a reliable resource for understanding Kura's position in precision oncology and its approach to addressing high-need cancer populations.
Bookmark this page for direct access to Kura Oncology's verified announcements. For comprehensive analysis of these developments, consult your financial advisor and review SEC filings in conjunction with these updates.
Kura Oncology (KURA) announced two abstracts from the KOMET-007 combination trial of ziftomenib will be presented at the ASH Annual Meeting in San Diego (December 7-10, 2024). The trial combines ziftomenib with standard treatments in NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) patients.
Key highlights include: All four Phase 1a dose-escalation cohorts advanced to Phase 1b expansion at 600 mg; 100% of NPM1-m AML patients and 84% of KMT2A-r patients remained on study; No DLTs or ziftomenib-induced QTc prolongation reported. The data suggests promising safety profile and robust activity in combination with standard treatments.
Kura Oncology (Nasdaq: KURA) announced it will release its third quarter 2024 financial results after U.S. market close on Thursday, November 7, 2024. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day, featuring management's discussion of financial results and a corporate update. Investors can access the call via phone or watch the webcast through the company's website.
Cartography Biosciences has appointed Troy E. Wilson, Ph.D., J.D. as an independent director to its Board of Directors. Wilson, a 25-year biopharma industry veteran, is currently President, CEO, and co-founder of Kura Oncology (NASDAQ: KURA). He brings extensive experience in founding and leading biotech companies, including Avidity Biosciences, Araxes Pharma, and Wellspring Biosciences. Cartography, an oncology company developing antibody therapeutics, aims to leverage Wilson's expertise as it advances its pipeline of novel programs targeting tumors more precisely than existing treatments.
Kura Oncology (KURA) reported promising preclinical data for its menin inhibitor ziftomenib in treating gastrointestinal stromal tumors (GIST). The combination of ziftomenib and imatinib demonstrated robust antitumor activity in both imatinib-sensitive and resistant GIST models. The data shows the combination works through a synthetic lethal mechanism, with ziftomenib targeting epigenetic vulnerabilities in GIST tumors. Following FDA clearance of the IND application in August 2024, Kura plans to initiate a proof-of-concept study combining ziftomenib with imatinib in advanced GIST patients after imatinib failure in 1H 2025.
Kura Oncology (Nasdaq: KURA) announced upcoming presentations of new preclinical data for its next-generation farnesyl transferase inhibitor (FTI) KO-2806 at the EORTC-NCI-AACR Symposium in Barcelona. The data supports combining KO-2806 with KRASG12C inhibitors and pan-RAS inhibitors for cancer treatment.
Two presentations will showcase how KO-2806 can re-sensitize KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors and sensitize colorectal cancers to pan-RAS inhibition. The company believes KO-2806 could enhance antitumor activity and become a valuable combination partner for targeted therapies in large solid tumor indications.
Kura Oncology (Nasdaq: KURA) has announced the publication of its KOMET-001 Phase 1 study results for ziftomenib in The Lancet Oncology. The study evaluated the safety, tolerability, and clinical activity of ziftomenib in relapsed/refractory acute myeloid leukemia (AML). Key findings include:
1. Promising clinical activity with manageable toxicity in heavily pretreated patients.
2. Marrow blast reduction, neutrophil and platelet recovery, transfusion independence, and clearance of measurable residual disease.
3. Determination of the recommended phase 2 dose (RP2D).
The company has completed enrollment for the Phase 2 portion of KOMET-001, a registration-directed trial in patients with NPM1-mutant AML. Topline data from this trial is expected in early 2025.
Kura Oncology (Nasdaq: KURA) has appointed Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience to the clinical-stage biopharmaceutical company. He currently serves as a Senior Advisor at Frazier Healthcare Partners and has held executive positions at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, Genzyme, and Sanofi Oncology.
The appointment comes at a key inflection point for Kura Oncology as it advances its menin inhibitor and farnesyl transferase inhibitor (FTI) programs for cancer treatment. Dr. Vasconcelles' expertise in R&D, regulatory affairs, and leadership across various companies is expected to be valuable in progressing these therapies through clinical trials and towards commercialization.
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in the upcoming Cantor Global Healthcare Conference in New York. The company's President and CEO, Troy Wilson, Ph.D., J.D., is set to take part in a fireside chat on September 17, 2024, at 1:20 p.m. ET / 10:20 a.m. PT.
Interested parties can access a live audio webcast of the fireside chat through the investor section of Kura's website at www.kuraoncology.com. An archived replay will also be available after the live event concludes. This conference participation provides an opportunity for Kura Oncology to showcase its progress and engage with the healthcare investment community.
Kura Oncology (Nasdaq: KURA) reported Q2 2024 financial results and provided a corporate update. Key highlights:
- Completed enrollment in KOMET-001 trial of ziftomenib in R/R NPM1-mutant AML; topline data expected in early 2025
- Received Breakthrough Therapy Designation for ziftomenib in R/R NPM1-mutant AML
- Phase 1b expansion study of ziftomenib combinations now enrolling
- IND cleared for ziftomenib in GIST; proof-of-concept study to begin in early 2025
- First patient dosed in KO-2806 and adagrasib combination study in NSCLC
- $491.5 million cash runway into 2027
Q2 2024 financials: R&D expenses $39.7M, G&A expenses $16.7M, net loss $50.8M
Kura Oncology (Nasdaq: KURA) announced FDA clearance of an IND application for ziftomenib, their menin inhibitor, to treat advanced gastrointestinal stromal tumors (GIST). A Phase 1 study combining ziftomenib with imatinib is planned for early 2025. Preclinical data suggest this combination could resensitize patients to imatinib and induce durable responses in imatinib-resistant cases. GIST, the most common sarcoma, is typically treated with KIT inhibitors like imatinib. However, many patients develop resistance, limiting treatment options. Ziftomenib targets the menin-MLL complex, which regulates KIT expression in GIST cells. This marks the first IND clearance for a menin inhibitor in GIST treatment, potentially offering a new approach for patients with options.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
